|
Market Closed -
NSE India S.E.
05:51:01 2026-11-08 EST
|
5-day change | 1st Jan Change | ||
| 5,304.00 INR | +0.13% |
|
+3.73% | -3.68% |
| 10-12 | Alkem Laboratories Limited Announces Management Appointments, Effective October 12, 2026 | CI |
| 09-24 | Alkem Laboratories Limited Announces Resignation of Nitin Agrawal as Chief Financial Officer | CI |
Company Valuation: Alkem Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 432,909 | 406,055 | 590,890 | 583,680 | 633,575 | 634,173 | - | - |
| Change | - | -6.2% | 45.52% | -1.22% | 8.55% | 0.09% | - | - |
| Enterprise Value (EV) 1 | 433,805 | 393,853 | 587,236 | 578,678 | 632,481 | 621,048 | 605,988 | 596,792 |
| Change | - | -9.21% | 49.1% | -1.46% | 9.3% | -1.81% | -2.42% | -1.52% |
| P/E | 26.3x | 41.3x | 32.9x | 27x | 27.5x | 27.6x | 24x | 20.7x |
| PBR | 5.01x | 4.49x | 5.73x | 4.87x | 4.58x | 4.12x | 3.62x | 3.19x |
| PEG | - | -1x | 0.4x | 1.3x | 4.37x | -98.45x | 1.6x | 1.3x |
| Capitalization / Revenue | 4.07x | 3.5x | 4.66x | 4.5x | 4.31x | 3.8x | 3.41x | 3.1x |
| EV / Revenue | 4.08x | 3.4x | 4.64x | 4.46x | 4.3x | 3.72x | 3.26x | 2.92x |
| EV / EBITDA | 21.1x | 24.5x | 26.2x | 23x | 21x | 18.2x | 15.4x | 13.4x |
| EV / EBIT | 24.8x | 30.3x | 30.2x | 26.9x | 24.1x | 20.9x | 17.7x | 15.2x |
| EV / FCF | 55.4x | 27.1x | 33.3x | 45.3x | 42.8x | 60.2x | 29.7x | 23.4x |
| FCF Yield | 1.81% | 3.69% | 3% | 2.21% | 2.33% | 1.66% | 3.37% | 4.28% |
| Dividend per Share 2 | 34 | 25 | 40 | 45 | 53 | 50.29 | 55.4 | 63.85 |
| Rate of return | 0.94% | 0.74% | 0.81% | 0.92% | 1% | 0.95% | 1.04% | 1.2% |
| EPS 2 | 137.6 | 82.31 | 150.2 | 181.1 | 192.5 | 192 | 221 | 256.1 |
| Distribution rate | 24.7% | 30.4% | 26.6% | 24.8% | 27.5% | 26.2% | 25.1% | 24.9% |
| Net sales 1 | 106,342 | 115,993 | 126,676 | 129,645 | 147,123 | 166,949 | 186,008 | 204,727 |
| EBITDA 1 | 20,529 | 16,094 | 22,455 | 25,122 | 30,052 | 34,204 | 39,337 | 44,427 |
| EBIT 1 | 17,490 | 12,990 | 19,462 | 21,550 | 26,232 | 29,661 | 34,151 | 39,180 |
| Net income 1 | 16,456 | 9,842 | 17,958 | 21,655 | 23,018 | 23,147 | 27,276 | 31,030 |
| Net Debt 1 | 896.1 | -12,202 | -3,654 | -5,003 | -1,094 | -13,125 | -28,185 | -37,381 |
| Reference price 2 | 3,620.70 | 3,396.10 | 4,942.00 | 4,881.70 | 5,299.00 | 5,304.00 | 5,304.00 | 5,304.00 |
| Nbr of stocks (in thousands) | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | - | - |
| Announcement Date | 5/13/22 | 5/19/23 | 5/29/24 | 5/29/25 | 5/28/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.59x | 3.71x | 18.13x | 0.95% | 6.74B | |
| 39.62x | 13.42x | 28.51x | 0.5% | 1,206B | |
| 40.43x | 6.79x | 19.09x | 1.93% | 665B | |
| 37.52x | 8.51x | 17.57x | 2.38% | 515B | |
| 20.98x | 5.12x | 12.74x | 2.57% | 381B | |
| 97.18x | 5.94x | 25.33x | 2.32% | 362B | |
| 23.18x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.46x | 4.89x | 13.77x | 1.79% | 289B | |
| 23.75x | 7.3x | 13.55x | 2.19% | 249B | |
| -39.18x | 7.28x | 45.82x | 1.98% | 207B | |
| Average | 29.55x | 6.89x | 20.89x | 1.93% | 418.65B | |
| Weighted average by Cap. | 35.66x | 8.54x | 21.86x | 1.73% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALKEM Stock
- Valuation Alkem Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
